The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial
Abstract
We present the results of a multicenter clinical trial using Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) generated from EBV-seropositive blood donors to treat patients with EBV-positive posttransplantation lymphoproliferative disease (PTLD) on the basis of the best HLA match and specific in vitro cytotoxicity. Thirty-three PTLD patients who had failed on conventional therapy were enrolled. No adverse effects of CTL infusions were observed and the response rate (complete or partial) in 33 patients was 64% at 5 weeks and 52% at 6 months. Fourteen patients achieved a complete remission, 3 showed a partial response, and 16 had no response at 6 months (5 died before completing treatment). At 5 weeks, there was a significant trend toward better responses with higher numbers of CD4+ cells in infused CTL lines (P = .001) that were maintained at 6 months (P = .001). Patients receiving CTLs with closer HLA matching responded better at 6 months (P = .048). Female patients responded better than male patients, but the differences were not statistically significant. Our results show that allogeneic CTLs are a safe and rapid therapy for PTLD, bypassing the need to grow CTLs for individual patients. The response rate in this poor prognosis patient group is encouraging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Starzl, T. E., Porter, K. A., Iwatsuki, S., Rosenthal, J. T., Shaw, B. W., Atchison, R. W., Nalesnik, M., Ho, M., Griffith, B. P., Hakala, T. R., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90994-2 · Cited by 1,234
Rooney, C. M., Ng, C. Y. C., Loftin, S., Smith, C. A., Li, C., Krance, R. A., Brenner, M. K., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91150-2 · Cited by 1,173
Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report
Opelz, G., & Döhler, B. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00325.x · Cited by 1,081
Heslop, H. E., Ng, C. Y. C., Li, C., Smith, C. A., Loftin, S. K., Krance, R. A., Brenner, M. K., & Rooney, C. M. (1996) · Nature Medicine · doi:10.1038/nm0596-551 · Cited by 821
Pope, J. H., Horne, M. K., & Scott, W. M. (1968) · International Journal of Cancer · doi:10.1002/ijc.2910030619 · Cited by 472
Haque, T., Wilkie, G. M., Taylor, C., Amlot, P. L., Murad, P., Iley, A., Dombagoda, D., Britton, K. M., Swerdlow, A. J., & Crawford, D. H. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09672-1 · Cited by 363
Self-citationGustafsson, A., Levitsky, V., Zou, J.-Z., Frisan, T., Dalianis, T., Ljungman, P., Ringden, O., Winiarski, J., Ernberg, I., & Masucci, M. G. (2000) · Blood · doi:10.1182/blood.v95.3.807.003k24_807_814 · Cited by 330
Khanna, R., Bell, S. C., Sherritt, M. A., Galbraith, A. J., Burrows, S. R., Rafter, L., Clarke, B., Slaughter, R., Falk, M. C., Douglass, J. A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10391 · Cited by 329
Cited by
Heslop, H. E., Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R. J., et al. (2010) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 780
Dojcinov, S. D., Venkataraman, G., Raffeld, M., Pittaluga, S., & Jaffe, E. S. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf8622 · Cited by 571
Leen, A. M., Bollard, C. M., Mendizabal, A. M., Shpall, E. J., Szabolcs, P., Antin, J. H., Kapoor, N., Pai, S.-Y., Rowley, S. D., Kebriaei, P., et al. (2013) · Blood · doi:10.1182/blood-2013-02-486324 · Cited by 553
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections
Odumade, O. A., Hogquist, K. A., & Balfour, H. H. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00044-10 · Cited by 458
Metadata
- Authors
- Haque, T., Wilkie, G. M., Jones, M. M., Higgins, C. D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P. L., Kelly, D., MacGilchrist, A., Gandhi, M. K., Swerdlow, A. J., & Crawford, D. H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-08-15
- Volume
- 110
- Issue
- 4
- Pages
- 1123-1131
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2153549003
- Cited by
- 648
- References
- 20
- FWCI
- 19.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. https://app.cochat.ai/papers/10.1182/blood-2006-12-063008
- The paper
- Haque, T., Wilkie, G. M., Jones, M. M., Higgins, C. D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P. L., Kelly, D., MacGilchrist, A., Gandhi, M. K., Swerdlow, A. J., & Crawford, D. H. (2007). Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. https://doi.org/10.1182/blood-2006-12-063008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.